PROTECT: Teplizumab Preserves Beta-Cell Function in Newly Diagnosed Type 1 Diabetes
In the PROTECT trial, teplizumab preserved β-cell function in newly diagnosed type 1 diabetes patients, slowing the decline of C-peptide levels, but key secondary endpoints, such as time in range and HbA1c, showed numerical trends without statistical significance.